Open AccessE2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
Author(s) -
Roisín M. Connolly,
Fengmin Zhao,
Kathy D. Miller,
Min-Jung Lee,
Richard Piekarz,
Karen L. Smith,
Ursa BrownGlaberman,
Jennifer S. Winn,
Bryan A. Faller,
Adedayo A. Onitilo,
Mark E. Burkard,
G. Thomas Budd,
Ellis Levine,
Melanie Royce,
Peter A. Kaufman,
Alexandra Thomas,
Jane B. Trepel,
Antonio C. Wolff,
Joseph A. Sparano
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.00944
Subject(s) - medicine , exemestane , breast cancer , oncology , fulvestrant , aromatase inhibitor , clinical endpoint , cancer , neutropenia , metastatic breast cancer , palbociclib , estrogen receptor , randomized controlled trial , chemotherapy , aromatase
Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement in progression-free survival (PFS) and overall survival (OS) with the addition of entinostat to the steroidal aromatase inhibitor (AI) exemestane in advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.